Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 2Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 41OTHER 2NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

bosutinib 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × Has announcements × Clear all
NCT04258943 2025-09-18

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Active not recruiting
60 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1/2 Completed
122 enrolled 24 charts 2 FDA
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡